Medically reviewed by Drugs.com. Last updated on Jan 22, 2019.
(aye GAL si days BAY ta)
- Alpha-Galactosidase-A (Recombinant)
- r-h α-GAL
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Reconstituted, Intravenous [preservative free]:
Fabrazyme: 5 mg (1 ea); 35 mg (1 ea) [contains mouse (murine) and/or hamster protein]
Brand Names: U.S.
Agalsidase beta is a recombinant form of the enzyme alpha-galactosidase-A, which is required for the hydrolysis of GL-3 and other glycosphingolipids. The compounds may accumulate (over many years) within the tissues of patients with Fabry disease, leading to renal and cardiovascular complications. In clinical trials of limited duration, agalsidase been noted to reduce tissue inclusions of a key sphingolipid (GL-3). It is believed that long-term enzyme replacement may reduce clinical manifestations of renal failure, cardiomyopathy, and stroke. However, the relationship to a reduction in clinical manifestations has not been established.
Vdss: Children: 247 to 1097 mL/kg; Adults: 81 to 570 mL/kg
Clearance: Children: 1.1 to 5.8 mL/minute/kg; Adults: 0.8 to 4.9 mL/minute/kg
Dose dependent: Children: 86 to 151 minutes; Adults: 45 to 119 minutes
Use: Labeled Indications
Fabry disease: For use in patients with Fabry disease. Agalsidase beta reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types.
There are no contraindications listed within the manufacturer's labeling.
Fabry disease: IV: 1 mg/kg every 2 weeks
Refer to adult dosing.
Fabry Disease: Children ≥8 years and Adolescents: IV: 1 mg/kg/dose every 2 weeks
Dosing adjustment for toxicity: Children ≥8 years and Adolescents: Patients with IgE antibodies or a positive skin test to agalsidase beta (rechallenge): IV: 0.5 mg/kg every 2 weeks at an initial maximum infusion rate of 0.01 mg/minute; may gradually escalate dose (to maximum of 1 mg/kg every 2 weeks) and/or infusion rate (doubling the infusion rate every 30 minutes to a maximum rate of 0.25 mg/minute) as tolerated.
Dosing: Adjustment for Toxicity
Patient with IgE antibodies or a positive skin test to agalsidase beta (rechallenge): IV: 0.5 mg/kg every 2 weeks at an initial maximum infusion rate of 0.01 mg/minute; may gradually escalate dose (to maximum of 1 mg/kg every 2 weeks) and/or infusion rate (doubling the infusion rate every 30 minutes to a maximum rate of 0.25 mg/minute) as tolerated.
IV: Allow vials and diluent to reach room temperature prior to reconstitution (~30 minutes). Each 35 mg vial should be reconstituted with 7.2 mL SWFI; reconstitute 5 mg vials with 1.1 mL SWFI; inject down internal side wall of vial; roll and tilt gently; do not shake. Resulting solution contains 5 mg/mL. Do not use filter needle to prepare. To make final infusion solution, add the desired amount of reconstituted solution to NS to make a final volume based on patient weight (see table for dilution volumes). Prior to adding the volume of agalsidase beta dose to the NS, remove an equal volume of NS. Avoid vigorous shaking or agitation.
Minimum Total Volume
35.1 - 70
70.1 - 100
Table has been converted to the following text:
Recommended minimum total volume for dilution
Patient weight ≤35 kg: 50 mL
Patient weight 35.1 - 70 kg: 100 mL
Patient weight 70.1 - 100 kg: 250 mL
Patient weight >100 kg: 500 mL
IV: Antipyretics should be administered prior to infusion. Infuse through a low protein binding 0.2 micron in-line filter. Initial infusion rate should not exceed 0.25 mg/minute (15 mg/hour). Interrupt or decrease rate in the event of an infusion reaction; may be restarted after resolution of symptoms and/or after administration of antipyretics, antihistamines, and/or steroids. After patient tolerance to the infusion is established, rate may be increased in increments of 0.05-0.08 mg/minute (3-5 mg/hour) with each subsequent infusion. Maximum infusion rate: Patients <30 kg: 0.25 mg/minute; patients ≥30 kg: Infuse over at least 1.5 hours. An initial maximum infusion rate of 0.01 mg/minute should be used for rechallenge in patients with IgE antibodies or who have had a positive skin test to agalsidase beta; may increase infusion rate (doubling the infusion rate every 30 minutes) to a maximum rate of 0.25 mg/minute as tolerated.
Store intact vials between 2°C and 8°C (36°F and 46°F). Product is preservative free; use reconstituted and solutions diluted in NS immediately. If not used immediately, reconstituted and diluted solutions are stable for 24 hours at 2°C and 8°C (36°F and 46°F).
Amiodarone: May diminish the therapeutic effect of Agalsidase Beta. Avoid combination
Chloroquine: May diminish the therapeutic effect of Agalsidase Beta. Avoid combination
Gentamicin (Systemic): May diminish the therapeutic effect of Agalsidase Beta. Avoid combination
Cardiovascular: Peripheral edema (21%), hypertension (14%)
Central nervous system: Chills (43%), headache (39%), paresthesia (31%), fatigue (24%), dizziness (21%), pain (16%), sensation of cold (11%)
Dermatologic: Skin rash (20%)
Immunologic: Development of IgG Antibodies (69% to 79%)
Local: Infusion site reaction (59%)
Neuromuscular & skeletal: Limb pain (19%), back pain (16%), myalgia (14%)
Respiratory: Upper respiratory tract infection (44%), cough (33%), nasal congestion (19%), lower respiratory tract infection (18%)
Miscellaneous: Fever (39%)
1% to 10%:
Cardiovascular: Tachycardia (9%), bradycardia (≥5%), chest pain (≥5%), facial edema (≥5%), flushing (≥5%), hypotension (≥5%), chest discomfort (5%)
Central nervous system: Anxiety (6%), burning sensation (6%), depression (6%), falling (6%), drowsiness (≥5%)
Dermatologic: Pruritus (10%), excoriation (9%), pallor (≥5%), urticaria (≥5%)
Endocrine & metabolic: Hot flash (5%)
Gastrointestinal: Toothache (6%), abdominal pain (≥5%), diarrhea (≥5%), nausea (≥5%), vomiting (≥5%)
Hypersensitivity: Anaphylaxis (≤1%), hypersensitivity reaction (≤1%)
Infection: Fungal infection (5%), viral infection (5%)
Neuromuscular & skeletal: Muscle spasm (5%)
Otic: Tinnitus (8%), hypoacusis (5%)
Renal: Increased serum creatinine (9%)
Respiratory: Sinusitis (9%), dyspnea (8%), respiratory congestion (8%), pharyngitis (6%), wheezing (6%), pharyngeal edema (≥5%)
Frequency not defined:
Cardiovascular: Cardiac arrhythmia, low cardiac output
Central nervous system: Ataxia, vertigo
Genitourinary: Nephrotic syndrome
<1%, postmarketing, and/or case reports: Angioedema, arthralgia, asthenia, bronchospasm, cardiac failure, cerebrovascular accident, dysphagia, erythema, hyperhidrosis, hypersensitivity angiitis, hypoesthesia, hypoxia, increased lacrimation, lymphadenopathy, myocardial infarction, oral hypoesthesia, palpitations, pneumonia, renal failure, respiratory failure, rhinorrhea, sepsis
Concerns related to adverse effects:
• Anaphylaxis/allergic reactions: Life-threatening anaphylactic and severe allergic reactions have been reported. Reactions may include angioedema, bronchospasm, chest discomfort, dysphagia, dyspnea, flushing, hypotension, nasal congestion, pruritus, rash, and urticaria. Stop infusion if severe reactions occur; immediate medical support should be readily available. Use caution when administering to patients with history of an anaphylactic or severe allergic reaction.
• Antibody formation: Development of IgG antibodies is common and has been observed within 3 months from the onset of therapy. Some patients may also develop IgE antibodies or skin test reactivity; consider IgE testing in patients with allergic reaction. Rechallenge of patients with IgE-mediated reaction or who have had a positive skin test may be done with caution.
• Infusion reactions: Infusion-related reactions are common, and may be severe (chills, vomiting, hypotension, paresthesia); pretreatment with antipyretics and antihistamines is advised. Decrease infusion rate, temporarily discontinue infusion, and/or administer additional antipyretics, antihistamines, and/or steroids to manage infusion reactions. Immediate discontinuation of infusion should be considered for severe reactions. Appropriate medical support for the management of infusion reactions should be readily available. Infusion reactions have occurred despite premedication. Use with caution when readministering to patients with history of infusion reactions.
• Cardiovascular disease: Use with caution in patients with cardiovascular disease; may have increased risk of complications from infusion reactions; monitor closely.
• Registry: A registry has been created to monitor therapeutic responses and adverse effects during long-term treatment, as well as effects on pregnant and breast-feeding women and their offspring; patients should be encouraged to register (www.registrynxt.com or 1-800-745-4447).
Development of IgG or IgE antibodies in patients with suspected allergic reactions (test available from manufacturer). Monitor for infusion-related reactions.
Information related to the use of agalsidase beta in pregnancy is limited (Germain 2010; Madsen 2019; Politei 2010; Senocak Tasci 2015).
Data collection to monitor pregnancy and infant outcomes following exposure to Fabrazyme is ongoing. Pregnant females may enroll in the Fabry registry by calling 1-(800)-745-4447 extension 15500 (www.registrynxt.com).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience common cold symptoms, cough, anxiety, muscle spasm, pharyngitis, tooth pain, or back pain. Have patient report immediately to prescriber hearing impairment, hearing loss, tinnitus, depression, dizziness, passing out, shortness of breath, or signs of infusion reactions (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about agalsidase beta
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: lysosomal enzymes
Other brands: Fabrazyme